Find Canertinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 267243-28-7, Ci-1033, Pd-183805, Canertinib (ci-1033), Canertinib free base, N-(4-(3-chloro-4-fluorophenylamino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide
Molecular Formula
C24H25ClFN5O3
Molecular Weight
485.9  g/mol
InChI Key
OMZCMEYTWSXEPZ-UHFFFAOYSA-N
FDA UNII
C78W1K5ASF

Canertinib
Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.
1 2D Structure

Canertinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide
2.1.2 InChI
InChI=1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29)
2.1.3 InChI Key
OMZCMEYTWSXEPZ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
2.2 Other Identifiers
2.2.1 UNII
C78W1K5ASF
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Ci 1033

2. Ci-1033

3. Ci1033

2.3.2 Depositor-Supplied Synonyms

1. 267243-28-7

2. Ci-1033

3. Pd-183805

4. Canertinib (ci-1033)

5. Canertinib Free Base

6. N-(4-(3-chloro-4-fluorophenylamino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide

7. N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide

8. C78w1k5asf

9. Chembl31965

10. N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide

11. Chebi:61399

12. 267243-28-7 (free Base)

13. N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide

14. Ncgc00182713-01

15. Pd183805

16. Canertinib [inn]

17. Canertinib [inn:ban]

18. Sn-26606

19. Ci-1033(canertinib)

20. Ci1033

21. Unii-c78w1k5asf

22. Canetinib

23. Canertinib [mi]

24. Caneritinib; Ci-1033

25. Canertinib - Ci-1033

26. Ci-1033 (canertinib)

27. Canertinib [who-dd]

28. Dsstox_cid_28869

29. Dsstox_rid_83138

30. Dsstox_gsid_48943

31. Schembl54837

32. Mls004774146

33. Pd 183805 Dihydrochloride

34. Bdbm4779

35. Cid_156414

36. Gtpl5675

37. Dtxsid8048943

38. Ex-a078

39. Bcpp000301

40. Hms3244m17

41. Hms3244m18

42. Hms3244n17

43. Bcp01790

44. Tox21_113361

45. Nsc780019

46. Nsc801011

47. S1019

48. Zinc27439698

49. Akos005145818

50. Bcp9000481

51. Bcp9000482

52. Bcp9000525

53. Ccg-269588

54. Cs-0121

55. Db05424

56. Nsc-780019

57. Nsc-801011

58. Sb16594

59. N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide

60. N-[4-(3-chloro-4-fluoro-anilino)-7-(3-morpholinopropoxy)quinazolin-6-yl]prop-2-enamide

61. Ncgc00182713-02

62. Ncgc00182713-18

63. As-56189

64. Hy-10367

65. Smr003500789

66. Pd0183805

67. Cas-267243-28-7

68. Ft-0654215

69. Ec-000.2258

70. A25038

71. 499c452

72. Q5032274

73. 2-propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-

74. N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide

75. N-[4-(3-chloro-4-fluoro-phenyl-amino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide

2.4 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 485.9 g/mol
Molecular Formula C24H25ClFN5O3
XLogP33.9
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count8
Rotatable Bond Count9
Exact Mass485.1629955 g/mol
Monoisotopic Mass485.1629955 g/mol
Topological Polar Surface Area88.6 Ų
Heavy Atom Count34
Formal Charge0
Complexity671
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Investigated for use/treatment in breast cancer and lung cancer.


5 Pharmacology and Biochemistry
5.1 Mechanism of Action

CI-1033 effectively inhibits the growth of esophageal squamous cell carcinoma which co-expresses both EGFR and HER2 with the inhibition of phosphorylation of both MAPK and AKT. Some studies suggest that CI-1033 holds significant clinical potential in esophageal cancer.


ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty